Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice.
Hyperhomocysteinemia, or abnormally high plasma homocysteine (Hcy) concentration, has often been associated with vascular thrombosis and the development of premature atherosclerosis. Many studies have shown that moderate wine consumption has potential beneficial effects related to the prevention of atherosclerosis, in part attributed to the biological properties of polyphenolic components, mainly flavonoids. The aim of the present study is to determine the effects of a red wine polyphenolic extract (PE) administration on hyperhomocysteinemia due to cystathionine beta-synthase (CBS) deficiency and on the associated biochemical markers of hepatic and endothelial dysfunctions in mice. Red wine PE was added for 4 weeks to the drinking water of heterozygous CBS-deficient mice fed a high-methionine diet, a murine model of hyperhomocysteinemia. Red wine PE supplementation at low dose significantly reduced plasma Hcy levels and restored the hepatic and plasma-decreased paraoxonase-1 activity induced by chronic hyperhomocysteinemia. Moreover, aortic expression of proinflammatory cytokines and adhesion molecules and levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 were reduced in hyperhomocysteinemic mice fed the red wine PE supplementation. These findings suggest that red wine PE administration in low quantities has beneficial effects on biochemical markers of endothelial dysfunction due to hyperhomocysteinemia.
Noll
Christophe
C
EA 3508, Université Paris Diderot - Paris 7, Paris, France.
Hamelet
Julien
J
Matulewicz
Ewelina
E
Paul
Jean-Louis
JL
Delabar
Jean-Maurice
JM
Janel
Nathalie
N
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001011:Aorta / Q000201:enzymology; D043303:Aryldialkylphosphatase / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D015415:Biomarkers; D002109:Caffeic Acids / Q000494:pharmacology; D003541:Cystathionine beta-Synthase / Q000172:deficiency / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006579:Heterozygote; D006710:Homocysteine / Q000097:blood; D020138:Hyperhomocysteinemia / Q000378:metabolism* / Q000517:prevention & control; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008715:Methionine / Q000008:administration & dosage / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology*; D059808:Polyphenols; D051131:Receptors, Oxidized LDL / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D014920:Wine
D000975:Antioxidants; D015415:Biomarkers; D002109:Caffeic Acids; D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols; D051131:Receptors, Oxidized LDL; D006710:Homocysteine; D008715:Methionine; D043303:Aryldialkylphosphatase; D003541:Cystathionine beta-Synthase; C040048:caffeic acid